New drug combo aims to shrink Hard-to-Treat sarcomas
NCT ID NCT03282344
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This phase 2 study tests whether combining NKTR-214 and nivolumab can shrink tumors in people with advanced sarcoma that has spread. About 88 participants aged 12 and older will receive the drug combination. The main goal is to see how many patients have their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.